Percepta is a genomic test that analyzes gene expression in lung cells collected during bronchoscopy to help diagnose lung cancer. When bronchoscopy results are inconclusive, Percepta can identify patients at low risk of cancer who may avoid invasive follow-up procedures. It has been validated in multiple studies of over 1,000 patients and is covered by Medicare. Percepta provides clinically actionable results and fits into current diagnostic workflows for evaluating patients with suspected lung cancer.

1. CLINICALLY PROVEN
COMPLEMENT TO LUNG
CANCER DIAGNOSTIC
BRONCHOSCOPIES
NOW
MEDICARE
COVERED

2. Intermediate pre-test risk
n=62
(P=0.01)
Percepta’s real-world registry data
demonstrates a 51% relative reduction in
invasive procedure recommendations6
37%
18%
INVASIVE PROCEDURES
WITHOUT PERCEPTA
INVASIVE PROCEDURES
WITH PERCEPTA
RELATIVE REDUCTION
51%
lung cancer diagnostic bronchoscopies
Bronchoscopy is recognized as the relatively
safe initial diagnostic procedure for patients
with suspected lung cancer1-7
OF LUNG CANCER BRONCHOSCOPY
PATHOLOGY RESULTS ARE
INCONCLUSIVE, WHERE THE
RESULT IS NOT DEFINITIVE1-4
40–60%
OF PATIENTS WITH INCONCLUSIVE
BRONCHOSCOPY RESULTS
UNDERGO FURTHER INVASIVE
PROCEDURES2
41%
Percepta improves the performance of

3. NEJM
2015
BMC MEDICAL
GENOMICS
2015
Percepta demonstrated clinical value
regardless of lesion size and location1
Sensitivity by Lesion Size
Bronchoscopy Bronchoscopy
+Percepta test +Percepta test
Percepta alone Percepta alone91%
81%
92%
90%
55%
58%
96%
95%
97%
97%
< 2 cm 2–3 cm
Sensitivity by Lesion Location
CENTRAL PERIPHERAL
55%
84%
multicenter prospective
medical centers1,2
studies, with over 1,000 patients and over 30
PERCEPTA IS VALIDATED FOR THE
ASSESSMENT OF PRIMARY LUNG
CANCER IN PATIENTS WHO1
:
• Are current or former smokers**
• Have no concurrent or prior cancer
• Are >21 years of age
HIGH NEGATIVE
PREDICTIVE VALUE1
91%*
PERCEPTA IDENTIFIES LOW RISK
PATIENTS TO AVOID INVASIVE
PROCEDURES
When bronchoscopy is inconclusive,
Percepta is proven to identify patients
with a low and very low risk of lung
cancer. These patients can avoid
further invasive procedures.
* Intermediate pre-test risk patients
**>100 cigarettes in a lifetime based on the AEGIS clinical validation study1
The Percepta Bronchial Genomic Classifier measures gene expression
alterations in bronchial epithelial cells collected from two brushings of the
main stem airway of current or former smokers
Percepta is supported by three independent

4. Percepta is fast and simple
to collect and order
Percepta fits seamlessly into your current lung
cancer diagnostic bronchoscopy protocol
Order a Percepta test when:
―― Bronchoscopy is inconclusive
Collect a Percepta sample for:
―― All lung cancer diagnostic
bronchoscopies
Easy to Collect Samples
• All-inclusive collection kit
• Two cytology brushes, with 8–10 brush passes from
normal appearing main stem bronchus (right anterior
and post anterior wall)
• Sample is collected at the start of each bronchoscopy,
without the need to sample the lesion directly
Easy to Order Test
• Access the Veracyte Portal from your computer at:
https://portal.veracyte.com/
Easy Reimbursement Support
• Percepta is covered by Medicare with no copayment
• The Veracyte Access Program provides financial
support for both uninsured and commercially insured
patients with financial need
Call a Veracyte client service representative at
844.464.5864 (844.464.LUNG) or email at ­
lung@veracyte.com
1
2
3

5. References:
1. Silvestri, et al. NEJM. 2015.
2. Whitney, et al. BMC Genomics. 2016.
3. Ost D, et al. American Journal of Resp
and Critical Care. 2016.
4. Tanner N, et al. CHEST. 2015.
5. Vachani, et al. CHEST. 2016.
Veracyte’s portfolio of actionable genomic tests is transforming diagnostics
with a new genomic standard of truth for thyroid cancer, lung cancer and
idiopathic pulmonary fibrosis. Gain clarity with the evidence-based answers
you need to make more informed treatment decisions.
VERACYTE IS YOUR PARTNER IN ADVANCING
DIAGNOSIS AND PATIENT CARE
40,000+ surgeries
avoided and counting8,9
20+ independent
clinical utility studies10,11
Included in 3 clinical
practice guidelines12-14
3 independent,
multicenter studies1,2
1,000+
patients enrolled1,2
30+
medical centers1,2
2 clinical validation
studies15,16
350+
patients enrolled
22+
medical centers15
6. Bronchial Genomic Classifier Abstract. CHEST. 2017.
7. Data on file at Veracyte, Inc.
8. Harrell RM, et al. AACE. 2017.
9. Data on file through Q4 2017.
10. Singer J, et al. CMRO. 2016.
11. SE, et al. Cancer Cytopathol. 2016.
12. Haugen BR, et al. Thyroid. 2016.
13. NCCN Thyroid Carcinoma Clinical Practice
Guidelines. Version 1. 2016.
14. Ross DS, et al. UpToDate. 2016.
15. Pankratz DG, et al. ANNALSATS. 2017
16. Brown et al. LANCET Submitted. 2017.
PC133.1.1801 © 2018 Veracyte, Inc. All rights reserved. The Veracyte and Percepta names and logos are marks of Veracyte, Inc. All other marks are the property of their
respective owners in the United States and other countries. FNAprotect is RNAprotect® cell reagent, manufactured by Qiagen®.
T 844.464.LUNG (844.464.5864)
T +1.650.243.6350 (International)
F 1.650.243.6388
E support@veracyte.com
6000 Shoreline Court, Suite 100
South San Francisco, CA 94080